Special Issue

Animal Experimental Findings for Health Effects of Radioactive Microparticles and Related Topics

Message from the Guest Editor

The effects of radiation on humans have been studied since the beginning of the research on people exposed to radiation in Hiroshima and Nagasaki, and have continued to the present. However, the effects of internal exposure to radioactive particles have not been considered as an issue until now. Recent studies, such as those of early entrants to the cities of Hiroshima and Nagasaki, we found the possibility of the new effects due to the radioactive dust. So, we began animal experiments to find the microparticle effects and found that we have been able to detect larger-than-expected exposure effects in animal studies using rats to examine the effects of microparticles including Mn-56. Therefore, we recognized the need for further systematic research on the most likely health effects of radioactive particles, and planned a special issue on related papers as a start. Keywords

- Internal exposure
- radioactive microparticles
- Mn-56
- radiation effects
- Hiroshima and Nagasaki
- Sempalatinsk
- animal experiments

Guest Editor

Dr. Masaharu Hoshi

The Center for Peace, Hiroshima University, Hiroshima 7300053, Japan

Deadline for manuscript submissions

closed (30 June 2021)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/71522

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).